We performed functional experiments on a melanoma model to evaluate the role of the PIK3CA H1047R mutation, a main enhancer of the Akt pathway, in drug resistance and evaluate the crosstalk existing between the MAPK and PI3K–Akt pathways (Figure 1). This evidence concerns the gene AKT1 and melanoma.